News Website

Pembrolizumab Monotherapy Improves PFS vs Chemotherapy in Frontline dMMR Endometrial Cancer - OncLive

Pembrolizumab Monotherapy Improves PFS vs Chemotherapy in Frontline dMMR Endometrial Cancer OncLive

Published: July 15, 2026, 3:58 p.m.

Read Full Article

KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy - BioSpace

KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy BioSpace

Published: July 15, 2026, 3:11 p.m.

Read Full Article

KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy - Business Wire

KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy Business Wire

Published: July 15, 2026, 10:45 a.m.

Read Full Article

What New MRI Research Reveals About Endometrial Cancer Staging and the 2023 FIGO Staging System - diagnosticimaging.com

What New MRI Research Reveals About Endometrial Cancer Staging and the 2023 FIGO Staging System diagnosticimaging.com

Published: July 1, 2026, 12:21 p.m.

Read Full Article

FAPI PET/MRI detects more endometriosis lesions than MRI alone - AuntMinnieEurope

FAPI PET/MRI detects more endometriosis lesions than MRI alone AuntMinnieEurope

Published: June 22, 2026, 9:16 p.m.

Read Full Article

Dostarlimab Provides Long-Term Benefits in dMMR/MSI-H Endometrial Cancer - OncLive

Dostarlimab Provides Long-Term Benefits in dMMR/MSI-H Endometrial Cancer OncLive

Published: June 20, 2026, 1:04 p.m.

Read Full Article

Nivolumab Produces 68% Clinical CR Rate in Resectable dMMR Endometrial Cancer - OncLive

Nivolumab Produces 68% Clinical CR Rate in Resectable dMMR Endometrial Cancer OncLive

Published: June 19, 2026, 5:49 p.m.

Read Full Article

Puxitatug Samrotecan Hits 60% Response Rate in Platinum- and IO-Pretreated Endometrial Cancer - Targeted Oncology

Puxitatug Samrotecan Hits 60% Response Rate in Platinum- and IO-Pretreated Endometrial Cancer Targeted Oncology

Published: June 19, 2026, 5:05 p.m.

Read Full Article

Immunotherapy in dMMR/MSI-H endometrial cancer – a true game-changer? - ESMO Daily Reporter

Immunotherapy in dMMR/MSI-H endometrial cancer – a true game-changer? ESMO Daily Reporter

Published: June 18, 2026, 2:24 p.m.

Read Full Article

PD-1 Inhibitors Improve Survival for dMMR Endometrial Cancer - Medscape Reference

PD-1 Inhibitors Improve Survival for dMMR Endometrial Cancer Medscape Reference

Published: June 17, 2026, 2:51 p.m.

Read Full Article

Latest Articles

Pembrolizumab Monotherapy Improves PFS vs Chemotherapy in Frontline dMMR Endometrial Cancer - OncLive

KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy - BioSpace

KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy - Business Wire

What New MRI Research Reveals About Endometrial Cancer Staging and the 2023 FIGO Staging System - diagnosticimaging.com

FAPI PET/MRI detects more endometriosis lesions than MRI alone - AuntMinnieEurope

Dostarlimab Provides Long-Term Benefits in dMMR/MSI-H Endometrial Cancer - OncLive

Nivolumab Produces 68% Clinical CR Rate in Resectable dMMR Endometrial Cancer - OncLive

Puxitatug Samrotecan Hits 60% Response Rate in Platinum- and IO-Pretreated Endometrial Cancer - Targeted Oncology

Immunotherapy in dMMR/MSI-H endometrial cancer – a true game-changer? - ESMO Daily Reporter

PD-1 Inhibitors Improve Survival for dMMR Endometrial Cancer - Medscape Reference

Subscribe to Our Newsletter